Table 1.
Characteristics of included studies
| Study | Design | Number of patients/lesions | No. of PC diagnoses | Age, years (mean or median) | Gleason score threshold | PI-RADS version | PSA (mean or median) | MRI Tesla strength | Number of interpreters | Endorectal Coil | Biopsy or prostatectomy |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ahmed et al. 2017 | Prospective | 576 | 230 | 63 | ≥7 | 2 | 7 | 1.5 | 2 | No | Biopsy |
| Boesen et al. 2018 | Prospective | 289 | 88 | 64 | ≥7 | 1 | 12 | 3 | 1 | No | Biopsy |
| Jordan et al. 2017 | Retrospective | 282 | 81 | 67 | ≥7 | 2 | 9 | 3 | 1 | No | Biopsy |
| Toner et al. 2017 | Retrospective | 152 | 92 | 63 | ≥7 | 2 | 6 | 1.5 or 3 | 1 | NR | Prostatectomy |
| Thompson et al. 2016 | Retrospective | 344 | 141 | 63 | ≥7 | 2 | 5 | 1.5 or 3 | 2 | NR | Biopsy |
| Lista et al. 2015 | Prospective | 150 | 28 | 66 | ≥6 | 2 | 11 | 1.5 | NR | Yes | Biopsy |
| Zhao et al. 2016 | Retrospective | 372 | 155 | 69 | ≥7 | 2 | 15 | 3 | 2 | Yes | Biopsy |
| Grey et al. 2015 | Prospective | 201 | 77 | 65 | ≥6 | 2 | 13 | 1.5 | 1 | No | Biopsy |
| Numao et a. 2013 | Prospective | 351 | 126 | 65 | ≥7 | NR | 6 | 1.5 | 1 | No | Biopsy |
| Osses et al. 2016 | Retrospective | 156 | 63 | 68 | ≥7 | 1 | 11 | 3 | 2 | No | Mixed |
| Feng et al. 2016 | Retrospective | 401 | 150 | 64 | NR | Both | 44 | 3 | 2 | Yes | Biopsy |
| Salami et al. 2014 | Prospective | 175 | 83 | 65 | ≥7 | 2 | 7 | 3 | 3 | Yes | Mixed |
| Thompson et al. 2014 | Prospective | 150 | 51 | 62 | ≥7 | 2 | 6 | 1.5 or 3 | 2 | No | Mixed |
| Greer et al. 2017 | Retrospective | 268 | 244 | 62 | ≥7 | 2 | 7.09 | 3 | 9 | Yes | Prostatectomy |
| Mussi et al. 2017 | Retrospective | 118 | 48 | NR | ≥6 | 2 | 4.6 | 3 | 2 | No | Biopsy |
| Choi et al. 2019 | Retrospective | 113 | 84 | 65 | ≥7 | 2 | 7.9 | 3 | 2 | NR | Prostatectomy |
| Duan et al. 2019 | Retrospective | 231 | 58 | 65 | ≥7 | 2 | 6.8 | NR | 1 | NR | Biopsy |
| Donato et al. 2020 | Retrospective | 344 | 208 | 65 | ≥7 | Both | 6.8 | 3 | 5 | No | Biopsy |
| Gaur et al. 2018 | Prospective | 733 | 236 | 64 | ≥7 | 2 | 6.5 | 3 | 1 | Both | Biopsy |
| Hsieh et al. 2020 | Prospective | 102 | 24 | 65 | ≥7 | 2 | 7.78 | 3 | 1 | No | Biopsy |
| Lee et al. 2018 | Retrospective | 237 | 106 | 65 | ≥7 | 2 | 9.7 | 1.5 or 3 | 1 | No | biopsy |
| Luzzago et al. 2018 | Prospective | 250 | 117 | 63 | ≥7 | Both | 6.1 | 1.5 | 3 | No | Mixed |
| Pal et al. 2018 | Retrospective | 426 | 196 | 64 | ≥7 | 1 | 6.2 | 1.5 | 2 | No | Biopsy |
| Rozas et al. 2019 | Retrospective | 342 | 83 | NR | ≥7 | 2 | NR | 3 | 2 | No | Biopsy |
| Viana et al. 2018 | Retrospective | 98 | 38 | 60 | ≥6 | 2 | 6.3 | 3 | 2 | No | Biopsy |
| Zhang et al. 2018(1) | Prospective | 114 | 39 | 66 | ≥7 | 1 | 9.7 | 3 | 2 | No | Biopsy |
| Zhang et al. 2018 | Prospective | 123 | 67 | 66 | ≥7 | 1 | 11.1 | 3 | 2 | No | Biopsy |
| Westphalen et al. 2020 | Retrospective | 3,449 | 2,082 | 65 | ≥7 | 2 | 6.6 | 1.5 or 3 | NR | No | Biopsy |
PC, prostate cancer; PI-RADS, Prostate Imaging Reporting and Data System; PSA, prostate specific antigen; NR, not reported.